## STAFFORD-MILLER LIMITED

(company number 00318499)

(the "Company")

## STATEMENT OF COMPLIANCE MADE BY THE DIRECTORS OF THE COMPANY

This is a statement for the purposes of section 644(5) of the Companies Act 2006 (the "Act").

We, the undersigned, being all the directors of the Company as at the date of this statement, make the following statement under section 644(5) of the Act:

As set out in the written resolutions circulated to the members of the Company on 27 November 2020, the Company proposes to reduce its capital by means of the solvency statement procedure under section 642 of the Act. The directors of the Company signed a solvency statement in the form prescribed by the Companies (Reduction of Share Capital) Order 2008 and section 643 of the Act (the "Solvency Statement") on 27 November 2020 and the special resolution approving the reduction of capital (the "Resolution") was passed on 27 November 2020.

We confirm that the Solvency Statement was:

- 1. made not more than 15 days before the date on which the Resolution was passed; and
- 2. provided to each member of the Company in accordance with section 642(2) of the Act.

Dated: 27 November 2020

Signed

Nicholas Cooper

Nicholas Cooper

Director

John Sadler

for and on behalf of Edinburgh Pharmaceutical Industries Limited

Director

11-14-

Thomas Whittle

**Director** 

John Sadler

for and on behalf of Glaxo Group Limited

Director

\*A9J5VIT5\* A06 04/12/2020

i

AUO

COMPANIES HOUSE